Moderna price target lowered to $168 from $210 at Barclays

Barclays lowered the firm’s price target on Moderna to $168 from $210 and keeps an Overweight rating on the shares. Moderna reported a Q3 modest beat while guiding to lower sales in 2024, the firm said in a research note on Friday. Revenue expected to grow in 2025 after flu and combo vaccine launch and break even in 2026. The headwind is already reflected in the stock and Barclays remains constructive on long-term growth potential, driven largely by respiratory and cancer franchises.